BRAF突变尾腺癌与结直肠癌不同,但对BRAF向治疗有反应
Vinay K Pattalachinti1,2, Emaan Haque1, Mahmoud Yousef1
1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
NPJ precision oncology
|February 5, 2025
概括
尾腺癌 (AA) 与BRAFV600E突变不同于结直肠癌 (CRC). BRAFV600EAA显示了对BRAFV600E+EGFR抑制的有希望的反应,这表明了潜在的向治疗.
科学领域:
- 胃肠道瘤学 胃肠道瘤学
- 分子诊断学 分子诊断
- 癌症基因组学 癌症基因组学
背景情况:
- 尾腺癌 (AA) 是一种罕见的恶性瘤,缺乏FDA批准的向疗法.
- BRAF突变是AA中罕见的驱动因素,与它们在结直肠癌 (CRC) 中既定的作用不同.
研究的目的:
- 将BRAF突变AA的临床病理和分子特征与BRAF突变CRC的临床病理和分子特征进行比较.
- 为了评估BRAFV600E和EGFR抑制在BRAFV600E突变AA.的有效性.
主要方法:
- 对BRAF突变的尾腺癌病例的回顾性分析.
- 与BRAF突变结直肠癌的一组进行比较分析.
- 在一组患者中评估对BRAFV600E+EGFR抑制的治疗反应.
主要成果:
- BRAF突变发生在3%的AA病例中.
- 在AA中BRAFV600E与不良预后,女性性别,微卫星不稳定性,粘膜组织学或差异化不相关,与CRC发现形成鲜明对比.
- 在AA和CRC中,BRAFV600E突变与其他Ras激活突变相互排斥.
- 在BRAFV600E+EGFR抑制实现了80%的疾病控制率和7.1个月的中位数无进展存活在BRAFV600EAA.AA.中.
结论:
- 与CRC相比,BRAFV600E-突变AA呈现出明显的临床病理特征.
- 结合BRAFV600E和EGFR抑制表明BRAFV600E-突变尾腺癌的治疗潜力.
更多相关视频
07:49Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
6.0K
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
13.6K
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
